secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pulmonx Corp (LUNG)
CIK:        0001127537
Form:       8-K
Filed at:   2023-05-02T23:59:59+00:00
Accession:  0001127537-23-000014
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pulmonx Q1 revenue $14.5M (+35% YoY); reaffirms FY 2023 guidance
----------------------------------------------------------------

- Worldwide revenue $14.5M, up 35% YoY; U.S. revenue $9.3M (+55% YoY).
- Gross margin 73% vs. 75% in Q1 2022; net loss $15.9M ($0.42 per share).
- Adjusted EBITDA loss $11.2M vs. $11.8M in prior-year period.
- Added 15 new U.S. Zephyr Valve treatment centers in Q1 2023.
- Full-year 2023 guidance reaffirmed: revenue $63-65M; gross margin 73-74%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1127537/000112753723000014/0001127537-23-000014-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1127537/000112753723000014/lung-20230502.htm
  HTML page:      https://secwatch.observer/filing/0001127537-23-000014

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer